<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

FDA Approves Fenfluramine for Lennox-Gastaut Syndrome Phase 3 Clinical Data Finds It Is Effective

Default sub title

minute read

The US Food and Drug Administration approved fenfluramine for Lennox-Gastaut syndrome based on data that found that the frequency of certain seizure subtypes, notably generalized tonic-clonic seizures, dropped in a dose-dependent way compared with a group taking placebo.

Topics: Press Coverage